CYP2C19基因型与氯吡格雷治疗后P2Y12反应单位的关联:前瞻性观察研究
该前瞻性观察研究纳入35例接受21天双联抗血小板治疗的非心源性轻型急性缺血性卒中或高危TIA成人患者,发现CYP2C19功能缺失携带者平均P2Y12反应单位显著高于非携带者(265 vs. 161,p<0.01),高血小板反应性也更常见(83% vs. 21%,p<0.01),但P2Y12反应单位与30天卒中复发无关。
要点
- CYP2C19功能缺失携带者平均P2Y12反应单位显著更高(265 vs. 161)。
- 功能缺失携带者高血小板反应性比例更高(83% vs. 21%)。
- P2Y12反应单位与30天卒中复发无显著关联。
核心结论
- 在轻型急性缺血性卒中或高危TIA接受双联抗血小板治疗的患者中,P2Y12反应单位随CYP2C19基因型变化,提示其可作为基因检测不可及时的氯吡格雷无反应替代标志物。
- 但P2Y12反应单位与短期临床结局无关。
研究设计与样本
- 前瞻性观察研究,纳入成人非心源性轻型急性缺血性卒中或高危TIA患者,接受21天双联抗血小板治疗,主要分析35例。
主要发现
- CYP2C19功能缺失携带者占17%,其平均P2Y12反应单位显著高于非携带者(265 vs. 161,p<0.01)。
- 高血小板反应性(P2Y12反应单位≥208)在携带者中更常见(83% vs. 21%,p<0.01)。
- 事后应用ABCD-GENE评分未改善对高血小板反应性或临床结局的预测。
关键数值与推荐
- 高血小板反应性定义为P2Y12反应单位≥208。
- P2Y12反应单位在氯吡格雷负荷剂量后≥12小时测量。
临床怎么用
- 在无法进行CYP2C19基因检测时,可考虑用P2Y12反应单位评估氯吡格雷反应性,但需注意其与短期临床结局无关。
局限性
- 观察性设计。
- P2Y12反应单位与短期临床结局无关联,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Recurrent stroke accounts for substantial morbidity and mortality worldwide, with up to 25% of ischemic strokes occurring in patients with prior strokes. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel is standard for secondary prevention after minor acute ischemic stroke (AIS) or high-risk transient ischemic attack (TIA). However, clopidogrel efficacy is reduced in carriers of cytochrome P450 2C19 (CYP2C19) loss-of-function (LOF) alleles. Although genotype-guided DAPT has been shown to improve outcomes, the limited availability, high cost, and turnaround time of CYP2C19 genotyping constrain real-world use. P2Y12 reaction units (PRUs) measured by the VerifyNow P2Y12 assay represent a potentially accessible alternative, but their relevance in the cerebrovascular population remains unclear. OBJECTIVE: To investigate the viability of PRUs as a surrogate biomarker for clopidogrel resistance, we aimed to assess the association of PRUs with CYP2C19 genotype, which has been previously proven as predictive of clinical outcomes in patients receiving DAPT after AIS. METHODS: We conducted a prospective observational study of adults with non-cardioembolic minor AIS or high-risk TIA treated with 21 days of DAPT between December 2021 and May 2023. PRUs were measured ≥ 12 h after a clopidogrel loading dose. The primary outcome was the group difference in PRUs by CYP2C19 LOF carrier status. Secondary outcomes included associations between high platelet reactivity (PRU ≥ 208), CYP2C19 genotype, and 30-day stroke recurrence. RESULTS: Of the 35 patients included in the primary analysis, 17% were CYP2C19 LOF carriers. Mean PRUs were significantly higher in LOF carriers (265 vs. 161; p < 0.01), and high platelet reactivity was more frequent among carriers (83% vs. 21%; p < 0.01) compared with noncarriers, respectively. Twenty-seven patients completed 30-day follow-up; 26% reported recurrent stroke symptoms, but neither CYP2C19 LOF status nor high platelet reactivity was associated. Post hoc application of the ABCD-GENE score did not improve prediction of high platelet reactivity or clinical outcomes. CONCLUSIONS: PRUs appear to vary by CYP2C19 genotype in patients receiving DAPT after minor AIS or TIA, suggesting utility as a surrogate marker of clopidogrel nonresponse when genotyping is unavailable. However, PRUs were not associated with short-term clinical outcomes.
引用
- Stone RM, Smith A, Gunter S, et al. Association Between CYP2C19 Genotype and P2Y12 Reaction Units in Patients Receiving Clopidogrel After Acute Ischemic Stroke: A Prospective, Observational Study. Pharmacotherapy. 2026. PMID: 42723528. doi:10.1002/phar.70201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。